Cagri + Sema (5mg + 5mg)

Buy Cagri Sema Blend | Proven Dual Amylin/GLP-1 Receptor Metabolic Research Stack | PrimaLab Peptide

The Cagri+Sema blend is a co-lyophilized dual metabolic research formulation combining Cagrilintide 5mg (a long-acting amylin analogue) and Semaglutide 5mg (a GLP-1 receptor agonist) in a single vial. Researchers who buy Cagri Sema blend use it to investigate dual amylin receptor and GLP-1 receptor (GLP-1R) co-activation in metabolic research models — exploring how the simultaneous engagement of two independent but complementary satiety and glucose regulation pathways affects energy homeostasis, appetite signalling, gastric motility, and body weight regulation in controlled preclinical research settings. PrimaLab Peptide supplies research-grade Cagri+Sema blend at ≥99.2% purity for both components, independently verified by Janoshik Analytical via HPLC and mass spectrometry, with a full batch-specific Certificate of Analysis included with every order.

What Is the Cagri+Sema Blend?

Cagri+Sema is a single co-lyophilized research vial containing two distinct research peptides — not two separate vials. Each component targets a different metabolic receptor, creating a dual-pathway research formulation:

Cagrilintide (Cagrilintide / IBI362-amylin component) — 5mg
Cagrilintide is a long-acting acylated amylin analogue. Amylin (islet amyloid polypeptide, IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells, playing important roles in glucose homeostasis, gastric emptying rate regulation, and central satiety signalling. Cagrilintide’s long-acting profile is achieved through acylation enabling albumin binding — extending its half-life substantially compared to native amylin or the approved amylin analogue pramlintide. Cagrilintide acts primarily on amylin receptors (AMYR1-3, which are complexes of calcitonin receptor with receptor activity-modifying proteins) expressed in the area postrema, nucleus tractus solitarius, and hypothalamus — brain regions central to energy balance regulation. Full details: Cagrilitide product page.

Semaglutide — 5mg
Semaglutide is a GLP-1 receptor agonist sharing approximately 94% structural similarity with endogenous human GLP-1, with fatty acid acylation enabling albumin binding for extended half-life. It acts on GLP-1 receptors expressed in the pancreas, gastrointestinal tract, brain, and heart — stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and activating central appetite suppression pathways through GLP-1R in the hypothalamus and brainstem. Full details: Semaglutide product page.

The Dual Receptor Research Rationale

The scientific rationale for combining Cagrilintide and Semaglutide in metabolic research derives from the complementary but mechanistically independent nature of amylin receptor and GLP-1R activation:

• Non-overlapping receptor targets: Cagrilintide acts on amylin receptors (AMYR) in the area postrema and hypothalamus; Semaglutide acts on GLP-1R in pancreatic beta cells, gastrointestinal tract, hypothalamus, and brainstem. These are distinct receptor populations with different signalling cascades and partially different anatomical distributions
• Complementary central satiety pathways: Both amylin receptors and GLP-1R are expressed in brain regions regulating energy intake and satiety, but through different signal transduction mechanisms. Research explores whether dual receptor co-activation produces additive or synergistic effects on central appetite regulation
• Distinct peripheral mechanisms: Amylin receptor activation has particular effects on gastric emptying rate and glucagon suppression that differ mechanistically from GLP-1R-mediated gastric emptying and glucagon suppression, allowing research into pathway-specific contributions
• Comparative research design: The Cagri+Sema combination allows direct comparison of dual amylin/GLP-1R co-activation against single-receptor GLP-1R agonism (Semaglutide alone) and against dual GIP/GLP-1R agonism (Tirzepatide) — enabling systematic investigation of how different receptor combination strategies affect metabolic research outcomes

Published research examining amylin/GLP-1 combination approaches is available through PubMed research on amylin and GLP-1 co-agonism and the broader NIH-archived review of dual peptide hormone combination strategies in metabolic research.

Cagri+Sema in the Multi-Receptor Agonist Research Landscape

The Cagri+Sema blend occupies a distinct position in PrimaLab Peptide’s metabolic research catalog, offering a unique amylin/GLP-1R dual-pathway combination not available through any other single product:

• Semaglutide: GLP-1R single agonist — the reference GLP-1R comparator
• Cagri+Sema (this product): Amylin receptor + GLP-1R dual pathway — the only amylin/GLP-1 combination in our catalog
• Tirzepatide: GIP receptor + GLP-1R dual agonist
• Mazdutide: GLP-1R + glucagon receptor (GCGR) dual agonist
• Retatrutide: GLP-1R + GIP receptor + GCGR triple agonist

This range of mechanistically distinct metabolic research compounds allows researchers to systematically investigate the contributions of different receptor pathway combinations to metabolic outcomes. Browse the complete Metabolic Peptides category and Peptide Blends & Stacks for the full range.

Purity & Third-Party Testing

Every batch of Cagri+Sema blend is independently tested by Janoshik Analytical using:

• HPLC (High-Performance Liquid Chromatography) — quantitative purity determination for both components at ≥99.2%
• Mass Spectrometry — molecular identity confirmation for both Cagrilintide and Semaglutide components

For a co-lyophilized blend, HPLC must resolve and quantify both peptide components independently — confirming that each compound is present at the specified quantity and purity level. The batch-specific COA is included with every order and cross-referenceable on the Janoshik database. Always review the COA before use in any research protocol.

Storage & Reconstitution

• Before reconstitution (sealed, lyophilized): Store at −20°C. Protect from moisture. Avoid repeated freeze-thaw cycles of the sealed lyophilized vial
• After reconstitution: Store at 2–8°C (standard lab refrigerator). Use within 28 days. Do not refreeze reconstituted solution
• Reconstitution solvent: Reconstitute with sterile Bacteriostatic Water (BAC Water). BAC Water is essential for multi-use vial access over the 28-day post-reconstitution window — the bacteriostatic preservation maintains sterility across multiple draws. Add solvent slowly down the inside vial wall — never directly onto the lyophilized powder. Swirl gently — do not shake or vortex
• Dissolution: Allow 2–5 minutes for complete dissolution. The reconstituted solution should be clear and colourless
• Aliquoting: If your protocol requires multiple uses from the same batch over an extended period, aliquot before storage to minimise repeated freeze-thaw exposure

Product Specifications

Product Name	Cagri+Sema (Cagrilintide 5mg + Semaglutide 5mg)
Component 1	Cagrilintide (long-acting amylin analogue) — 5mg
Component 2	Semaglutide (GLP-1 receptor agonist) — 5mg
Total Peptide Content	10mg per vial
Form	Co-lyophilized powder, single vial
Purity	≥99.2% for both components (Janoshik HPLC + MS verified)
Testing Laboratory	Janoshik Analytical (independent third-party)
COA	Batch-specific — included with every order
Storage (sealed)	−20°C, protect from moisture
Storage (reconstituted)	2–8°C, use within 28 days — do not refreeze
Reconstitution Solvent	Bacteriostatic Water (BAC Water)
Intended Use	Laboratory and research use only — not for human or animal use

Frequently Asked Questions — Cagri+Sema Blend

What is the Cagri+Sema blend used for in research?

Researchers who buy Cagri Sema blend use it to investigate dual amylin receptor and GLP-1R co-activation effects on energy homeostasis, appetite and satiety signalling through complementary central pathway mechanisms, gastric emptying rate modulation, glucagon suppression, and body weight regulation in preclinical research models. The combination allows systematic comparison of dual amylin/GLP-1R pathway co-activation against single-receptor GLP-1R agonism and against other dual receptor combinations such as GIP/GLP-1R (Tirzepatide) or GLP-1R/GCGR (Mazdutide). Published research on the dual amylin/GLP-1 approach is available on PubMed.

Why does combining Cagrilintide and Semaglutide make sense as a research formulation?

Cagrilintide and Semaglutide target completely independent receptor populations — amylin receptors (AMYR1-3, expressed primarily in the area postrema and hypothalamus) and GLP-1R (expressed in pancreas, gut, and brain) respectively. Because these receptor systems use different signal transduction pathways and have partially different anatomical distributions, their co-activation allows research into additive or synergistic effects on metabolic outcomes that cannot be achieved by either compound alone. This non-overlapping receptor targeting is the core scientific rationale for the Cagri+Sema research combination.

Is the Cagri+Sema blend independently tested?

Yes. Every batch is independently verified by Janoshik Analytical at ≥99.2% purity for both components via HPLC and mass spectrometry identity confirmation. The batch-specific COA is included with every order. For a co-lyophilized blend, Janoshik’s HPLC analysis resolves and quantifies both peptide components independently — confirming that each is present at the specified quantity and purity level.

How does the Cagri+Sema blend differ from Tirzepatide?

Tirzepatide is a dual GIP receptor + GLP-1R agonist — combining GIP receptor (glucose-dependent insulinotropic polypeptide receptor) and GLP-1R engagement in a single molecule. The Cagri+Sema blend combines amylin receptor (AMYR) co-activation (Cagrilintide) with GLP-1R agonism (Semaglutide) — substituting GIP receptor engagement with amylin receptor engagement. These are fundamentally different receptor combinations with distinct downstream signalling cascades, anatomical distributions, and research-relevant metabolic effects. Both are available from PrimaLab Peptide for comparative multi-receptor research.

Can I order Cagrilintide and Semaglutide as individual compounds instead?

Yes. Both components are available as standalone research peptides from PrimaLab Peptide: Cagrilitide (Cagrilintide) and Semaglutide. The individual compounds are appropriate for research designs requiring custom ratios, single-compound controls, or independent study of each receptor pathway. The pre-blended Cagri+Sema vial is designed for research programs where both components at 5mg + 5mg is the confirmed study requirement.

What reconstitution solvent should I use for the Cagri+Sema blend?

Reconstitute with sterile Bacteriostatic Water (BAC Water). BAC Water is essential for this multi-use research blend — the 0.9% benzyl alcohol bacteriostatic preservation maintains sterility across multiple draws over the 28-day post-reconstitution window. Add BAC Water slowly down the inside vial wall, swirl gently (never shake), allow full dissolution, and store at 2–8°C. Do not refreeze the reconstituted solution.

Related Research Peptides

Researchers buying Cagri Sema blend for dual amylin/GLP-1 metabolic research frequently explore:

• Cagrilitide (Cagrilintide) — long-acting amylin analogue available as standalone research peptide
• Semaglutide — GLP-1R agonist available as standalone research peptide
• Tirzepatide — dual GIP/GLP-1R agonist for comparative dual receptor research
• Mazdutide — dual GLP-1R/GCGR agonist for comparative dual receptor research
• Retatrutide — triple GLP-1R/GIP/GCGR agonist for comprehensive multi-receptor research
• AOD9604 — modified GH fragment for complementary fat metabolism research

Browse our complete Peptide Blends & Stacks and Metabolic Peptides categories. Bulk researchers and laboratory procurement teams can apply for discounted rates through our Wholesale Portal. Reconstitute with BAC Water, available in our Accessories & Reconstitution Supplies section.

⚠️ For laboratory and research use only. Not approved for human or animal administration. Not intended for diagnosis, treatment, cure, or prevention of any disease or condition. All products are intended exclusively for in-vitro laboratory research. Researchers are solely responsible for compliance with all applicable local, national, and international regulations governing the purchase, storage, and use of research compounds.